Downgrade to Sell – 2026 Guidance at Risk, 2030 Targets Stretched

Research evidence excerpt

Downgrade to Sell – 2026 Guidance at Risk, 2030 Targets Stretched

17 June 2026

Life Sciences Tools & Diagnostics

Diasorin

testing. The GI franchise, in particular, continues to evolve toward an integrated

diagnostic ecosystem, combining multiple assays across the patient journey, while

innovations such as Calprotectin HD aim to improve clinical decision-making.

At the same time, Diasorin is leveraging guideline changes to expand testing

volumes in areas such as hypertension, where new screening recommendations

could significantly increase the total addressable market. Additionally, MeMed

represents a potential longer-term growth driver, contingent on reimbursement

expansion, given its demonstrated ability to reduce inappropriate antibiotic usage.

Overall, Diasorin plans to launch more than 20 new specialty assays by 2030.

Despite these opportunities, immunodiagnostics growth is expected to moderate

compared to the past decade, reflecting normalization effects post-COVID,

increased pricing pressure and the potential impact of competition in key segments

such as latent TB.

Molecular diagnostics: the primary growth engine

Molecular diagnostics is clearly positioned as the key growth driver, with

management targeting a low double-digit growth rate in 2026, accelerating to high-

teens through 2030. This implies a significant shift in the group’s revenue mix, with

molecular expected to nearly double its contribution to group revenues over the

period.

The strategy is built around three complementary platforms. The LIAISON NES

addresses decentralized testing in point-of-care environments, offering rapid

turnaround times and simplified workflows tailored to physician offices and urgent

care settings. The LIAISON Plex platform introduces flexibility into multiplex